MURRIETA, CA--(Marketwire - November 13, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today released its November 2008 investor newsletter, which highlights the pending close of the company's acquisition of ThyroTest® through the issuance of preferred stock and a note in the amount of $750,000. ThyroTest® is a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.
